Also being developed for second-line treatment of metastatic BRAF V600E mutation-positive non-small cell lung cancer.
If you have a Hayes login, click here to view the full report on the Knowledge Center.
Also being developed for second-line treatment of metastatic BRAF V600E mutation-positive non-small cell lung cancer.
If you have a Hayes login, click here to view the full report on the Knowledge Center.